Specific mutations in the cholesterol-binding site of APP alter its processing and favor the production of shorter, less toxic Aβ peptides

Hanbouch, L. et al. (2022) Specific mutations in the cholesterol-binding site of APP alter its processing and favor the production of shorter, less toxic Aβ peptides. Molecular Neurobiology, 59(11), pp. 7056-7073. (doi: 10.1007/s12035-022-03025-9) (PMID:36076005) (PMCID:PMC9525381)

[img] Text
280246.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Excess brain cholesterol is strongly implicated in the pathogenesis of Alzheimer’s disease (AD). Here we evaluated how the presence of a cholesterol-binding site (CBS) in the transmembrane and juxtamembrane regions of the amyloid precursor protein (APP) regulates its processing. We generated nine point mutations in the APP gene, changing the charge and/or hydrophobicity of the amino-acids which were previously shown as part of the CBS. Most mutations triggered a reduction of amyloid-β peptides Aβ40 and Aβ42 secretion from transiently transfected HEK293T cells. Only the mutations at position 28 of Aβ in the APP sequence resulted in a concomitant significant increase in the production of shorter Aβ peptides. Mass spectrometry (MS) confirmed the predominance of Aβx-33 and Aβx-34 with the APPK28A mutant. The enzymatic activity of α-, β-, and γ-secretases remained unchanged in cells expressing all mutants. Similarly, subcellular localization of the mutants in early endosomes did not differ from the APPWT protein. A transient increase of plasma membrane cholesterol enhanced the production of Aβ40 and Aβ42 by APPWT, an effect absent in APPK28A mutant. Finally, WT but not CBS mutant Aβ derived peptides bound to cholesterol-rich exosomes. Collectively, the present data revealed a major role of juxtamembrane amino acids of the APP CBS in modulating the production of toxic Aβ species. More generally, they underpin the role of cholesterol in the pathophysiology of AD.

Item Type:Articles
Keywords:Alzheimer’s disease, mutant, cholesterol, Aβ, amyloid precursor protein.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Millan, Dr Mark
Authors: Hanbouch, L., Schaack, B., Kasri, A., Fontaine, G., Gkanatsiou, E., Brinkmalm, G., Camporesi, E., Portelius, E., Blennow, K., Mourier, G., Gilles, N., Millan, M. J., Marquer, C., Zetterberg, H., Boussicault, L., and Potier, M.-C.
College/School:College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience
Journal Name:Molecular Neurobiology
Publisher:Springer
ISSN:0893-7648
ISSN (Online):1559-1182
Published Online:09 September 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Molecular Neurobiology 59(11): 7056-7073
Publisher Policy:Reproduced under a Creative Commons License
Data DOI:10.5281/zenodo.6274232

University Staff: Request a correction | Enlighten Editors: Update this record